Literature DB >> 33486762

Non-Hodgkin lymphoma after treatment for classical Hodgkin lymphoma: a report from the German Hodgkin Study Group.

Dennis A Eichenauer1,2, Horst Müller1,2, Leonard Elger1,2, Helen Goergen1,2, Michael Fuchs1,2, Stefanie Kreissl1,2, Boris Böll1,2, Volker Diehl2, Bastian von Tresckow2,3, Peter Borchmann1,2, Andreas Engert1,2.   

Abstract

Data on non-Hodgkin lymphoma (NHL) after classical Hodgkin lymphoma (cHL) are scarce. We therefore performed a retrospective analysis comprising 11·841 cHL patients who had first-line treatment within the randomized German Hodgkin Study Group (GHSG) HD7-HD15 studies. After a median follow-up of 106 months, 175 patients (1·5%) had developed NHL. The median time to NHL was 44 months, the median age at NHL diagnosis was 54 years. The five-year event-free survival and overall survival estimates from the diagnosis of NHL were 36·9% and 44·2%, respectively. Thus, NHL after cHL is a rare event primarily affecting older individuals and often resulting in the patient´s death.
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  Classical Hodgkin lymphoma; incidence; non-Hodgkin lymphoma; prognosis; treatment

Year:  2021        PMID: 33486762     DOI: 10.1111/bjh.17327

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Common Variable Immunodeficiency-Associated Cancers: The Role of Clinical Phenotypes, Immunological and Genetic Factors.

Authors:  Luzia Bruns; Victoria Panagiota; Sandra von Hardenberg; Gunnar Schmidt; Ignatius Ryan Adriawan; Eleni Sogka; Stefanie Hirsch; Gerrit Ahrenstorf; Torsten Witte; Reinhold Ernst Schmidt; Faranaz Atschekzei; Georgios Sogkas
Journal:  Front Immunol       Date:  2022-02-17       Impact factor: 7.561

2.  Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma.

Authors:  Emilio Bellitti; Pierluigi Masciopinto; Pellegrino Musto; Elena Arcuti; Luca Mastracci; Giuseppina Opinto; Sabino Ciavarella; Attilio Guarini; Gerardo Cazzato; Giorgina Specchia; Eugenio Maiorano; Francesco Gaudio; Giuseppe Ingravallo
Journal:  Curr Oncol       Date:  2022-08-25       Impact factor: 3.109

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.